Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia
Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia
复制标题
DOI：
10.1111/j.1479-828x.2005.00366.x
复制
发表时间：
2005-04-01
影响因子：
1.7
通讯作者：
Hanjani, P
中科院分区：
文献类型：
--
作者：
Gilani, MM;Yarandi, F;Hanjani, P
甲氨蝶呤和更生霉素是治疗低危妊娠滋养细胞肿瘤（LRGTN）的有效药物。为了比较这两种药物在LRGTN中的有效性，46例患者随机接受每周肌肉注射甲氨蝶呤30 mg/m2（n = 28）或静脉注射更生霉素1.25 mg/m2（n = 18），每2周一次。甲氨蝶呤组14例（50%）和更生霉素组16例（89%）达到完全缓解。放线菌素D更大的患者便利性和更少的就诊次数使其优于其他替代品，上级。
Methotrexate and dactinomycin are efficient drugs in the treatment of patients with low-risk gestational trophoblastic neoplasia (LRGTN). To compare the effectiveness of these two drugs in LRGTN, 46 patients were randomised to receive weekly intramuscular methotrexate at 30 mg/m(2) (n = 28) or intravenous dactinomycin at 1.25 mg/m(2) every 2 weeks (n = 18). Fourteen patients (50%) in the methotrexate group and 16 patients (89%) in the dactinomycin group achieved complete response. Greater patient convenience and a lower number of required visits make dactinomycin superior to other alternatives.